At a glance
- Originator Wyeth
- Class Heart failure therapies
- Mechanism of Action Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hyponatraemia; Oedema
Most Recent Events
- 07 Aug 2009 Discontinued - Preclinical for Congestive heart failure in USA (PO)
- 07 Aug 2009 Discontinued - Preclinical for Hyponatraemia in USA (PO)
- 07 Aug 2009 Discontinued - Preclinical for Oedema in USA (PO)